Navigation Links
Shire Launches Nationwide Adult ADHD Mobile Awareness Tour
Date:5/12/2008

ADHD screening initiative launches in Atlanta and continues for 90 days; Shire expects up to 20,000 adults to self-screen for ADHD in 13 cities

across the country

PHILADELPHIA, May 12 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the launch of a 13-city mobile screening initiative for adults with Attention Deficit Hyperactivity Disorder (ADHD), a psychiatric disorder that affects approximately 4.4 percent of the U.S. adult population aged 18-44 according to the National Comorbidity Survey Replication, a nationally representative household survey. The screening initiative, launched in Atlanta, GA, is designed to help raise awareness that ADHD is not just a childhood disorder. Research shows it is estimated that up to 65 percent of children with ADHD will continue to exhibit symptoms into adulthood. Adults who think they may have ADHD can take the first step toward recognizing the symptoms of the disorder by answering the 6-question World Health Organization (W.H.O.) adult ADHD screener. The screening initiative, known as the "RoADHD Trip," is housed, transported and anchored by the RoADHD Trip Tractor Trailer which expands into a tented area housing eight self-screening stations.

"Shire developed this mobile screening initiative as a forum to educate the public about ADHD in adults and provide information and resources to individuals about this disorder," said Gerardo Torres, M.D., Vice President and Scientific Lead, of Shire's ADHD Business Unit. "This program demonstrates Shire's on-going commitment to providing information for those who may be struggling with the symptoms of ADHD."

In each of the 13 cities, Shire is partnering with the Attention Deficit Disorder Association (ADDA), a leading adult ADHD patient advocacy organization, in an effort to assist up to 20,000 adults to self-screen for this disorder. Volunteers from A
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
2. Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
3. New Shire Holding Company Proposal
4. Shire to Introduce a New UK Listed Holding Company
5. Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
6. Shire plc: Long Term Incentive Plan
7. Shire plc: IFRS Results for the Year Ending December 31, 2007
8. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
9. Shire plc: Correction Re Website
10. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
11. Shire Engages Palio

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., , SHANGHAI, Nov. 30 /PRNewswire... pharmaceutical, biotechnology, and medical-device... operations in China and the United States,announ...nology Fast 50 China,2009 list for the fifth conse...owing companies in China,s technology, media, and ...
(Date:11/27/2009)..., , DURHAM, N.C., Nov. 27 /PRNewswir...rk, will initiate water-soluble carbon nanotube-ba...a. The water-soluble carbon nanotubes, which have ...jugation with cancer drugs, was developed in partn...The conjugated carbon nanotubes serves as a drug d...
(Date:11/25/2009)..., , BOSTON, Nov. 25 ...e H1N1 virus, genomic data from the 1918 pandemic ...the current H1N1 pandemic, today issued its latest...hows that the lethality of the H1N1 ("Swine Flu") ...during the virus,s current outbreak in the spring ...
(Date:11/25/2009)..., , NEW YORK, Nov. 25 /PRNewswire/ -...earch report is available in its catalogue: ,, ...o 2013 ,, http://www.reportlinker.com/p016550...to-2013.html ,, Brazil Bioethanol Market Analy...e report provides detailed analysis and forecasts ...
Breaking Biology Technology:WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 10
..., Dec. 20 Conatus Pharmaceuticals Inc. today,anno...vel drug candidate,for the treatment of liver dise...ion in patients who have failed the approved stand... drug candidate, CTS-1027, is being studied as,a t...resulting from,infection by HCV. CTS-1027 inhibits...
... Calif., Dec. 20 Ardea Biosciences,Inc. (Nasdaq: ...velopment of,small-molecule therapeutics for the t...y diseases, today announced that it has entered in...stitutional investors to raise,approximately $40 m... 3.0,million newly issued shares of its common sto...
..., Dec. 20 /Xinhua-PRNewswire-FirstCall/ -- China T...TDC, "the Company" or "CTDC"), a,provider of clean...ing on,solar energy business in China, today annou...ategic plan to focus the Company,s management and,...olar energy., On December 18, 2007, the Company d...
Other Biology Technology:Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis 2Ardea Biosciences Announces $40 Million Private Placement 2Ardea Biosciences Announces $40 Million Private Placement 3CTDC Announces the Disposal of Non-core Business 2
(Date:11/30/2009)...erimental Biology are pleased to announce that Dr...e Scientifique (CNRS) in the Universit de Nice-Sop...utstanding Paper Prize. ,The prize is awarded in r...tended to encourage young scientists, says Hans H... ,we truly appreciate when authors submit their ve...
(Date:11/30/2009)... rise scientists are presented with the complex ch...dapt. In a paper published in Insect Conservation...d Dr Miguel Rodriguez assess this challenge. , T....6˚C has already affected the Earth,s biota a...volutionary biologists is to predict how biologica...
(Date:11/30/2009)...seeing your extended family over the holidays was ...in the December 2009 print issue of the Journal o...hows that you might be right. Here,s the good news...ly new treatments that help keep autoimmune diseas.... That,s because researchers from the University o...
Breaking Biology News(10 mins):French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4How can scientists measure evolutionary responses to climate change? 2Seeing family for the holidays? Scientists discover how the stress might kill you 2Association of Retired Xerox Employees Initiate Legal Proceedings Against Xerox Corporation 58522 1Association of Retired Xerox Employees Initiate Legal Proceedings Against Xerox Corporation 58522 2Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization 28IVF 29 5098 1Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization 28IVF 29 5098 2Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization 28IVF 29 5098 3Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 1Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 2Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 3Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 4Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 5Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 6
...en oxides produced by huge fires and fossil fuel c...They are the primary ingredients in ground-level o...tation. , But new research led by a University of ...me regions, nitrogen oxides emitted by the soil ar...tantially larger role in seasonal air pollution th...
...circulates in our bodies through a complex network...his network is, however, of major importance for t...ur body. Researchers from the Flanders Interuniver...ith the Catholic University of Leuven, are the fir...th the help of tadpoles. This accelerates research...
...ie Mellon CyLab computer scientist Yang Cai is wor...e (ESTO), the Goddard Space Flight Center (GSFC) a...tion (NOAA) to develop new software for detecting ...aters. , "We are developing software that will mon...lies for public health," said Cai, who noted other...
Other Biology News:Study uncovers dirty little secret: Soil emissions are much-bigger-than-expected component of air pollution 2Study uncovers dirty little secret: Soil emissions are much-bigger-than-expected component of air pollution 3Tadpole soon to help in the fight against cancer and lymphedema 2Tadpole soon to help in the fight against cancer and lymphedema 3Carnegie Mellon cyLab researchers work to develop new red tide monitoring 2
...k, Super-Small! Capture high-resolution chemilumi...c-It Imaging System. High-sensitivity camera is co...und noise and wide dynamic range for high quality ...abinet provides optimum conditions for chemilumine...
Goat Anti-Microbial Sarcosine Oxidase Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-Human ODZ1 Polyclonal Antibody, Unconjugated from Atlas Antibodies
Chicken Anti-HADHSC Azide Free Polyclonal Antibody, Unconjugated from Abcam
Biology Products: